Ticker

RUTHERFORD, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer, will present at LSI USA '26 Summit, taking place March 16-20, 2026, in Dana Point,…

RUTHERFORD, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that the US Patent and Trademark Office (USPTO) has issued Patent Nos. US 12,453,494, US 12,458,257, and US 12,458,258 for the Company's continuous blood…

GlucoTrack, Inc. (NASDAQ: GCTK - Get Free Report) shares traded up 2.9% during trading on Wednesday. The company traded as high as $4.20 and last traded at $3.91. 2,536,909 shares traded hands during mid-day trading, an increase of 8,894% from the average session volume of 28,208 shares. The stock had previously closed at $3.80. Analysts

Rutherford, NJ., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 1,033,591 shares of common stock (or common…

Shares of GlucoTrack, Inc. (NASDAQ: GCTK - Get Free Report) were down 2.2% on Tuesday. The stock traded as low as $4.45 and last traded at $4.50. Approximately 10,583 shares were traded during mid-day trading, a decline of 85% from the average daily volume of 69,123 shares. The stock had previously closed at $4.60. Analyst